1. Home
  2. Clinical Topics
  3. FDA approves first targeted therapy for bladder cancer
Clinical TopicsDrugs and DevicesOncologyOncology Resource CenterWeb Exclusives

FDA approves first targeted therapy for bladder cancer

Share

On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following previous platinum-containing chemotherapy.

Read more at fda.gov.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts